[Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. / Efficacité de l'imatinib dans les syndromes hyperéosinophiliques associés au transcrit FIP1L1-PDGFRA.
Rev Med Interne
; 29(1): 65-7, 2008 Jan.
Article
em Fr
| MEDLINE
| ID: mdl-18036706
ABSTRACT
Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by marked peripheral blood and tissue eosinophilia resulting in organ damage. Recent advances in molecular biology have led to the identification of a FIP1L1-PDGFRA fusion gene as a recurrent abnormality in some patients with HES. This fusion gene results from a cryptic 4q12 interstitial deletion involving an 800 kb region. Recent reports indicate that this subtype of HES is imatinib responsive with rapid and complete haematological remissions. Here we report two patients successfully treated with imatinib.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Proteínas de Fusão Oncogênica
/
Síndrome Hipereosinofílica
/
Receptor alfa de Fator de Crescimento Derivado de Plaquetas
/
Fatores de Poliadenilação e Clivagem de mRNA
/
Inibidores de Proteínas Quinases
Idioma:
Fr
Ano de publicação:
2008
Tipo de documento:
Article